Bioworld Insider
Rising to the COVID-19 challenge, clinical trials evolve
Share this episode
COVID-19’s impact on clinical trials has been broad and varied. Recruiting disruptions, protocol changes and logistical challenges have forced both investigators and regulators to adapt. As the pandemic continues to shape how trials are run, key stakeholders are responding with new ideas to keep drug candidates on track. Join us as we talk to Laurie Halloran, president and CEO of Boston-based Halloran Consulting, about the way trial sponsors and regulators have managed through this time. Working with more than 750 clients, from startups to global drug developers over 23 years, Halloran has seen it all and shares some of the strategies companies are using to succeed.
The BioWorld Insider Podcasts provides timely and focused one-on-one interviews with the same key sources typically interviewed for articles such as company founders, executives, top researchers and regulators. Topics are prioritized based on the same criteria we use when selecting news to feature in BioWorld, which for more than 30 years reports the breaking news — and provides key perspective — on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes.
